Classification Model to Estimate MIB-1 (Ki 67) Proliferation Index in NSCLC Patients Evaluated With 18F-FDG-PET/CT

Anticancer Res. 2020 Jun;40(6):3355-3360. doi: 10.21873/anticanres.14318.

Abstract

Background/aim: Proliferation biomarkers such as MIB-1 are strong predictors of clinical outcome and response to therapy in patients with non-small-cell lung cancer, but they require histological examination. In this work, we present a classification model to predict MIB-1 expression based on clinical parameters from positron emission tomography.

Patients and methods: We retrospectively evaluated 78 patients with histology-proven non-small-cell lung cancer (NSCLC) who underwent 18F-FDG-PET/CT for clinical examination. We stratified the population into a low and high proliferation group using MIB-1=25% as cut-off value. We built a predictive model based on binary classification trees to estimate the group label from the maximum standardized uptake value (SUVmax) and lesion diameter.

Results: The proposed model showed ability to predict the correct proliferation group with overall accuracy >82% (78% and 86% for the low- and high-proliferation group, respectively).

Conclusion: Our results indicate that radiotracer activity evaluated via SUVmax and lesion diameter are correlated with tumour proliferation index MIB-1.

Keywords: 18F-FDG PET/CT; MIB-1; artificial intelligence; non-small-cell lung cancer.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / classification*
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging*
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Cell Proliferation / physiology
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen / biosynthesis*
  • Lung Neoplasms / classification*
  • Lung Neoplasms / diagnostic imaging*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Male
  • Positron Emission Tomography Computed Tomography / methods
  • Radiopharmaceuticals
  • Retrospective Studies

Substances

  • Ki-67 Antigen
  • MKI67 protein, human
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18